Advancing diagnostics to address antibacterial resistance: The diagnostics and devices committee of the Antibacterial Resistance Leadership Group

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S41-S47

  Tsalik, Ephraim L ^a,b   Petzold, Elizabeth ^a   Kreiswirth, Barry N ^c   Bonomo, Robert A ^d,e   Banerjee, Ritu ^f   Lautenbach, Ebbing ^g   Evans, Scott R ^h   Hanson, Kimberly E ⁱ   Klausner, Jeffrey D ^j   Patel, Robin ^k   Caliendo, Angie ^l   Chiu, Charles ^l   Humphries, Romney ^l   Miller, Melissa ^l   Woods, Chris ^l  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Affairs Medical Center   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k MAYO CLINIC   (United States)

^l NONE

more..

Author keywords

Antibacterial Resistance; Devices; Diagnostics

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOBANK; BLOODSTREAM INFECTION; DIAGNOSTIC TEST; HUMAN; IMMUNE RESPONSE; LABORATORY; LEADERSHIP; LOWER RESPIRATORY TRACT INFECTION; MOLECULAR DIAGNOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STUDY DESIGN; BACTERIAL INFECTION; CLINICAL STUDY; HOST PATHOGEN INTERACTION; METHODOLOGY; MICROBIOLOGY; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; SEPSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL SPECIMEN BANKS; CLINICAL STUDIES AS TOPIC; DRUG RESISTANCE, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; LABORATORIES; LEADERSHIP; MOLECULAR DIAGNOSTIC TECHNIQUES; PROFESSIONAL STAFF COMMITTEES; RESEARCH DESIGN; SEPSIS;

EID: 85023188558     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw831     Document Type: Article

References (42)

1. Banerjee R, Teng CB, Cunningham SA, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis 2015;61:1071-80.
2. Evans SR, Hujer AM, Jiang H, et al; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016;62:181-9.
3. Evans S, Hujer A, Jiang H, et al. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against Acinetobacter spp. PRIMERS III. J Clin Microbiol 2016;55:134-44.
4. Evans SR, Pennello G, Pantoja-Galicia N, et al; Antibacterial Resistance Leadership Group. Benefit-risk evaluation for diagnostics: a framework (BED-FRAME). Clin Infect Dis 2016;63:812-7.
5. Evans S, Tran T, Hujer A, et al. Choosing ceftazidime/avibactam and ceftolozane/tazobactam as empiric therapies against Pseudomonas aeruginosa (Pa) using rapid molecular diagnostics (RMDs): PRIMERS IV. IDWeek. New Orleans, LA, 2016.
6. Patel R, Tsalik EL, Petzold E, et al. Viewpoint: MASTERMIND-bringing microbial diagnostics to the clinic. Clin Infect Dis 2017;64:355-60.
7. Huvane J, Komarow L, Hill C, et al. Fundamental and catalytic innovation: the Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S18-23.
8. Cross HR, Harris A, Arias RM, et al. Transforming concepts into clinical trials and creating a multisite network: the Leadership and Operations Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S8-12.
9. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
10. Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book 2015:e141-7.
11. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64:1-137.
12. Bauer KA, West JE, Balada-Llasat JM, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus/S. aureus blood culture test in patients with S. aureus bacteremia. Clin Infect Dis 2010;51:1074-80.
13. Forrest GN, Roghmann MC, Toombs LS, et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 2008;52:3558-63.
14. Huang AM, Newton D, Kunapuli A, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. Clin Infect Dis 2013;57:1237-45.
15. Perez KK, Olsen RJ, Musick WL, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Arch Pathol Lab Med 2013;137:1247-54.
16. Sango A, McCarter YS, Johnson D, Ferreira J, Guzman N, Jankowski CA. Stewardship approach for optimizing antimicrobial therapy through use of a rapid microarray assay on blood cultures positive for Enterococcus species. J Clin Microbiol 2013;51:4008-11.
17. Anderson DJ, Jenkins TC, Evans SR, et al. The role of stewardship in addressing antibacterial resistance: the Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S36-40.
18. Manca C, Hill C, Hujer AM, et al. Leading antibacterial laboratory research by integrating conventional and innovative approaches: the Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S13-7.
19. Gould IM. Antibiotic resistance: the perfect storm. Int J Antimicrob Agents 2009;34:S2-5.
20. Kim JH, Gallis HA. Observations on spiraling empiricism: its causes, allure, and perils, with particular reference to antibiotic therapy. Am J Med 1989;87:201-6.
21. Lee GC, Reveles KR, Attridge RT, et al. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med 2014;12:96.
22. The White House. Executive Order-Combating antibiotic-resistant bacteria. Office of the Press Secretary, 2014.
23. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87.
24. Hersh AL, Shapiro DJ, Pavia AT, Shah SS. Antibiotic prescribing in ambulatory pediatrics in the United States. Pediatrics 2011;128:1053-61.
25. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother 2014;69:234-40.
26. Huang Y, Zaas AK, Rao A, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLoS Genet 2011;7:e1002234.
27. McClain MT, Nicholson BP, Park L P, et al. A genomic signature of influenza infection shows potential for presymptomatic detection, guiding early therapy, and monitoring clinical responses. Open Forum Infect Dis 2016;3:ofw007.
28. Woods C W, McClain MT, Chen M, et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One 2013;8:e52198.
29. Zaas AK, Burke T, Chen M, et al. A host-based RT-PCR gene expression signature to identify acute respiratory viral infection. Sci Transl Med 2013;5:203ra126.
30. Zaas AK, Chen M, Varkey J, et al. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 2009;6:207-17.
31. Tsalik EL, Henao R, Nichols M, et al. Host gene expression classifiers diagnose acute respiratory illness etiology. Sci Transl Med 2016;8:322ra11.
32. Reitsma JB, Rutjes AW, Khan KS, Coomarasamy A, Bossuyt PM. A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol 2009;62:797-806.
33. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80.
34. Bossuyt PM, Reitsma JB, Bruns DE, et al; Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003;138:W1-12.
35. Whiting P, Rutjes A, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8:1-234.
36. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8.
37. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003;144:5578-84.
38. Albrich WC, Dusemund F, Bucher B, et al; ProREAL Study Team. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012;172:715-22.
39. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000-7; discussion 7-8.
40. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302:1059-66.
41. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; CD007498.
42. Doi Y, Bonomo RA, Hooper DC, et al. Gram-negative bacterial infections: research priorities, accomplishments, and future directions of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S30-5.